Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats ...

About Cellectar Biosciences, Inc.Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

On Monday, Oppenheimer reaffirmed its Perform rating for Cellectar Biosciences (NASDAQ:CLRB) shares, a micro-cap biotech currently ...

Blue-chip tech stocks are a big part of President Donald Trump's portfolio, according to his latest financial disclosures.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...